Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886992 | PMC |
| http://dx.doi.org/10.1007/s40336-018-0270-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Three-dimensional spatial localization and volume estimation of prostate tumors using F-PSMA-1007 PET/CT versus multiparametric MRI.
Eur J Nucl Med Mol Imaging
December 2024
Division of Urology, Department of Surgery, University of Alberta, Edmonton, Canada.
Purpose: Fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed tomography (F-PSMA-1007 PET/CT) has been shown to be superior to multiparametric magnetic resonance imaging (MRI) for the locoregional staging of intermediate-risk and high-risk prostate tumors. This study aims to evaluate whether it is also superior in estimating tumor parameters, such as three-dimensional spatial localization and volume.
Methods: 134 participants underwent F-PSMA-1007 PET/CT and MRI prior to radical prostatectomy as part of the validating paired-cohort Next Generation Trial (NCT05141760).
Performance of PSMA-PET/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer.
Skeletal Radiol
December 2024
Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 South Kingshighway Boulevard, Campus, Box 8131, St. Louis, MO, 63110, USA.
Objective: Prostate-specific membrane antigen (PSMA)-PET/CT has shown considerable promise in the evaluation of prostate cancer bone metastases; however, data utilizing a histopathologic reference standard in this setting are limited. We therefore sought to evaluate the diagnostic performance of PSMA-PET/CT using a consistent histopathologic gold standard in the form of bone biopsy.
Materials And Methods: In this single-center, retrospective study, we identified 80 patients with prostate cancer who underwent CT-guided bone biopsy of a tracer-avid osseous lesion on PSMA-PET/CT performed with F-piflufolastat.
Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer.
Eur Urol Open Sci
January 2025
Department of Urology, University of Turku and Turku University Hospital, Turku, Finland.
Background And Objective: Toxicity from local salvage therapy for radiorecurrent prostate cancer (PCa) remains a concern. This phase 2 study evaluates the outcomes of salvage magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (sTULSA).
Methods: Men with biochemically relapsed, biopsy-proven PCa following definitive radiotherapy underwent whole- or partial-gland sTULSA (NCT03350529).
PSMA-RADS to improve evaluation and management of prostate cancer.
Abdom Radiol (NY)
December 2024
University of California, Irvine, USA.
Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) / computed tomography (CT) has become essential in managing prostate cancer, offering superior diagnostic accuracy. The introduction of the U.S.
View Article and Find Full Text PDFThe accuracy of fluorine 18-labelled prostate-specific membrane antigen PET/CT and MRI for diagnosis of prostate cancer in PSA grey zone.
Br J Cancer
December 2024
PET/CT Center, The First Affiliated Hospital of Xi' an Jiaotong University, Xi' an, China.
Background: The diagnostic utility of prostate biopsy is limited for prostate cancer (PCa) in the prostate-specific antigen (PSA) grey zone. This study aims to evaluate the diagnostic performance of multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) for PSA grey zone PCa and clinically significant PCa (csPCa).
Methods: A total of 82 patients with PSA levels ranging from 4 to 10 ng/mL who underwent F-PSMA-1007 PET/CT, mpMRI, and prostate biopsy were prospectively enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!